Generic drug companies may be eligible for R&D tax credits for performing qualified research activities. For example, the following activities may be eligible for R&D tax credits:
-
Performing technical research including quality, reliability and effectiveness of generic drugs
-
Performing technical research and/or development including strengths, dosage forms, routes of administration, and indications to generic products
-
Performing technical research including value-added generics, hybrid generics, or new therapeutic entities (NTE) formulations
-
Developing and/or designing enhanced generic product production processes
-
Developing biosimilars in compliance with governmental standards of quality, safety, and efficacy
-
Developing techniques for the assessment of bioequivalence (e.g. range of dosage forms, delivery systems)
-
Developing an array of delivery technologies (e.g. extended-release, drug device combinations, alternative dosages)
-
Developing fixed combinations of commonly co-prescribed medicines (e.g. diuretic/potassium conserving and non-steroidal/proton pump inhibitor) to improve patient compliance
-
Designing cost reduction processes pursuant to government safety and efficacy regulations
-
Designing packaging and dispensing systems to improve efficiency, reduce waste, avoid dosing errors, or promote patient safety
-
Quality testing assurance to meet bioequivalent standards pursuant to health authority regulations and/or licensing